Interestingly, improved killing of B-cell lymphoma lines, including OCI-Ly2 and OCI-Ly19, Raji, Daudi, DEL (anaplastic large cell lymphoma model), Granta-519 and Jeko-1 (MCL), was triggered by the combination of anti-CD19-CAR-T cells with an anti-CD20-IFN fusion protein indicating that antibody-targeted IFN could improve the CAR-T cell therapy [100]. Here, IFNA1 is linked to B-cell non-Hodgkin lymphoma.